Allergan has struck a deal with two generic manufacturers to resolve a long-running patent infringement suit over its antidepressant drug Fetzima.
The US Food and Drug Administration has urged the US Patent and Trademark Office (USPTO) to curb drug costs in the wake of President Joe Biden’s plan to promote competition in the pharmaceutical sector.
Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.
Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.
The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict from being made.
The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.
The US Court of Appeals for the Federal Circuit has affirmed US Patent Trial and Appeal Board’s decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.
The US Court of Appeals for the Federal Circuit has affirmed a Delaware court ruling upholding the validity of cancer drug patents owned by Teva Pharmaceuticals.
The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.
Pharmaceutical companies Shionogi and Duchesnay have filed a second lawsuit against Hetero labs, claiming that the company infringed two additional patents related to Osphena—a treatment for vaginal pain during sex.